MERS-CoV-IN-1

MERS-CoV-IN-1 exhibits excellent inhibitory activity against coronavirus. MERS-CoV-IN-1 is useful as a pharmaceutical composition for preventing coronavirus-induced diseases (MERS-CoV and SARS) (extracted from patent WO2018174442A1, compound 1) [1].

Product Specifications

CAS Number

[2245697-92-9]

UNSPSC

12352005

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/mers-cov-in-1.html

Purity

99.53

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

NC1=C(C=CC=C1)COC(C=C2)=CC=C2OC3=CC=CC=C3

Molecular Formula

C19H17NO2

Molecular Weight

291.34

References & Citations

[1]Compound for treating diseases caused by coronavirus infection. Patent WO2018174442A1.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

MBS951085-01 0.02 mg (Mammalian-Cell)

Recombinant Human Carbonyl reductase [NADPH] 1 (CBR1), partial

Ask

View Details

MBS951085-02 0.02 mg (E-Coli)

Recombinant Human Carbonyl reductase [NADPH] 1 (CBR1), partial

Ask

View Details

MBS951085-03 0.1 mg (E-Coli)

Recombinant Human Carbonyl reductase [NADPH] 1 (CBR1), partial

Ask

View Details

MBS951085-04 0.1 mg (Mammalian-Cell)

Recombinant Human Carbonyl reductase [NADPH] 1 (CBR1), partial

Ask

View Details

MBS951085-05 1 mg (E-Coli)

Recombinant Human Carbonyl reductase [NADPH] 1 (CBR1), partial

Ask

View Details

MBS951085-06 1 mg (Mammalian-Cell)

Recombinant Human Carbonyl reductase [NADPH] 1 (CBR1), partial

Ask

View Details